Orchestra BioMed and Terumo Terminate Distribution Deal
Orchestra BioMed (Nasdaq:OBIO) announced a termination and right of first refusal agreement with Terumo regarding the Virtue Sirolimus AngioInfusion Balloon (SAB).
- The agreement supersedes and terminates a prior distribution agreement between the companies.
- Terumo gains a right of first refusal (ROFR) to acquire the rights or enter a distribution agreement for Virtue SAB in treating coronary artery disease (CAD).
- Terumo will pay Orchestra $10 million upfront for the ROFR.
Additionally, Terumo will invest $20 million in Orchestra BioMed through non-voting preferred stock.
Terumo previously made a $30 million non-refundable payment and $5 million common stock investment in Orchestra under the prior agreement.
The transactions are expected to close no later than November.
Author's summary: Orchestra BioMed and Terumo terminate distribution deal in $30M agreement.
More News
- Martyn Norsworthy scoops top portrait award
- 9 Black Actresses Who Went From Broadway To The Hollywood Big Screen
- Liverpool vs. Crystal Palace: Carabao Cup team news & TV info
- Gavin Newsom Says He Has 'No Interest' in Appearing on Joe Rogan's Podcast: 'I'm Moving On' | Video
- Lauri Markkanen first Jazz player to score 50 points since Karl Malone in win over Suns
- Patrick Mahomes’ immediate words on Travis Kelce after victory in the Chiefs Commanders game
- Randomly-textured lithium niobate gives snapshot spectrometer a boost – Physics World
- 10 Facts About NVIDIA–Nokia AI-RAN Partnership and $1 bn Investment for 6G Networks - TelecomLead
- Bitcoin Miner TeraWulf (WULF) Stock Jumps 25% On AI News
- Art the Clown Owes One of His 'Terrifier' Victims a Lot of Money